CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Total revenue	$ 10,546,612	$ 6,095,007	$ 29,048,825	$ 17,519,162
Cost of revenue	2,890,382	1,696,274	8,524,991	5,269,228
Gross margin	7,656,230	4,398,733	20,523,834	12,249,934
Other expenses:
Research and development	1,753,455	3,185,105	6,124,780	8,533,342
Legal, financial and other consulting	580,067	733,297	1,944,930	1,886,851
Selling, general and administrative	7,282,357	6,107,877	20,190,193	15,372,476
Total expenses	9,615,879	10,026,279	28,259,903	25,792,669
Loss from operations	(1,959,649)	(5,627,546)	(7,736,069)	(13,542,735)
Other income/(expense):
Interest expense, net	(260,617)	(301,972)	(839,972)	(721,703)
Gain (loss) on foreign currency transactions	1,380,537	(955,543)	1,416,577	(1,051,854)
Total other income (expense), net	1,119,920	(1,257,515)	576,605	(1,773,557)
Net loss before benefit from income taxes	(839,729)	(6,885,061)	(7,159,464)	(15,316,292)
Benefit from income taxes	0	0	0	0
Net loss attributable to common shareholders	$ (839,729)	$ (6,885,061)	$ (7,159,464)	$ (15,316,292)
Basic and diluted net loss per common share	$ (0.02)	$ (0.21)	$ (0.19)	$ (0.48)
Weighted average number of shares of common stock outstanding	41,593,218	32,365,700	37,350,564	32,189,430
Net loss	$ (839,729)	$ (6,885,061)	$ (7,159,464)	$ (15,316,292)
Other comprehensive income (loss):
Currency translation adjustment	(1,047,749)	811,763	(1,043,280)	868,243
Comprehensive loss	(1,887,478)	(6,073,298)	(8,202,744)	(14,448,049)
Product
Revenue:
Total revenue	10,245,642	5,728,463	27,921,940	16,155,459
Cyto Sorb Sales
Revenue:
Total revenue	10,245,642	5,648,463	27,852,940	16,008,659
Other Sales
Revenue:
Total revenue		80,000	69,000	146,800
Grant
Revenue:
Total revenue	$ 300,970	$ 366,544	$ 1,126,885	$ 1,363,703